GK News 2 - шаблон joomla Видео

Banner1

Log in
Powered by Spearhead Software Labs Joomla Facebook Like Button
10 May 2017
Naoual Benhmidou1, Fadoua Rais1, Fadila Kouhen2, Abdelhak Maghous1, Hasna Loughlimi1, Khadija Bellahammou3, Hanan Elkacemi1, Tayeb Kebdani1, Sanaa Elmajjaoui1, Noureddine Benjaafar1 1)
10 May 2017
Khadija Bellahammou1, Asmaa Lakhdissi1,
10 May 2017
Khaled Moursy Salama1, Monira T.
02 April 2017
Bardia Bidarmaghz, Ryo Mizumoto, Rasika

HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE

freedigitalsphotos.net freedigitalsphotos.net

Ivan Inkov1, Desislava Penkova2, George Baytchev1, Zdravko Kamenov3, Mila Kayriakova3, Dimo Manov3

1) Department Of Thoracic Surgery, Military Medical Academy, Sofia, Bulgaria.

2) Novartis Oncology; Novartis Pharmaceutical Corporation, Sofia, Bulgaria.

3) Medical University of Sofia, Sofia, Bulgaria

Disclosure: The author has declared no conflicts of interest.

Accepted: 30.04.16

Citation: http://dx.doi.org/10.5455/ijsm.pi3kinhibitorbreastcancer

Abstract:

Breast cancer is a heterogenous disease, showing as several different clinical and histologic types. Most of breast cancers express hormone receptors for estrogen and progesterone, which are considered as estrogen receptor-positive and progesterone-receptor-positive, respectively.

Endocrine therapy was the first class of target-directed therapy approved for treating breast cancer and is still very important for the treatment of HR+ breast cancer because of its effectiveness and good toxicity profile. It targets receptor-mediated signaling pathways implicated in cell survival and proliferation, such as those mediated by hormone receptors. Although these approaches have improved the management of advanced breast cancer, many patients either fail to respond to initial therapy (primary or de novo resistance) or eventually become resistant to treatment (secondary or acquired resistance). To expand the use of existing endocrine treatments and their efficiency, new methods are needed. Such new approaches would boost the benefit of existing endocrine therapy by extending time to disease progression, avoiding or overcoming resistance to endocrine treatment, and delaying the use of chemotherapy.

This article will review the central role of the PI3K inhibitors in driving ER+/HER2- breast tumors. Also, schemes to combine pathway inhibitors with endocrine therapy for better patient outcome, and approaches to identify patient populations that would benefit most from inhibition of the PI3K/AKT/mTOR pathway will be assessed.

Abstract & Fulltext

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

 09 May 2017
  192  
Fazlý Yanýk1; Gonul Sagiroglu2; Elif Copuroglu2; Yekta Altemur Karamustafaoglu1
 192 
Fazlý Yanýk1; Gonul Sagiroglu2; Elif Copuroglu2; Yekta Altemur Karamustafaoglu1
09 May 2017
 28 March 2017
  305  
Zuvdija Cecunjanin1, Amina Selimovic2, Selma Milisic1, Ermina Mujicic3
 305 
Zuvdija Cecunjanin1, Amina Selimovic2, Selma Milisic1, Ermina Mujicic3
28 March 2017
 28 March 2017
  656  
Michele Bisaccia1, Luigi Piscitelli1, Giovanni Colleruoli1, Giuseppe Rinonapoli1, Cristina Ibáñez Vicente1, Gabriele Falzarano2, Antonio Medici2, Luigi Meccariello3, Olga Bisaccia4, ...
 656 
Michele Bisaccia1, Luigi Piscitelli1, Giovanni Colleruoli1, Giuseppe Rinonapoli1, Cristina Ibáñez Vicente1, Gabriele Falzarano2, ...
28 March 2017
 26 March 2017
  327  
Roman Romansky1, George Baytchev2, Ivan Inkov2, Stefan Komitski1
 327 
Roman Romansky1, George Baytchev2, Ivan Inkov2, Stefan Komitski1
26 March 2017
 26 March 2017
  243  
Andrea Cappiello1, Verdiana Stano2, Michele Bisaccia1, Luigi Meccariello3, Gabriele Falzarano4, Antonio Medici4, Marco Pellegrino1, Olga Bisaccia5, Giuseppe Rinonapoli1, Auro Caraffa1.
 243 
Andrea Cappiello1, Verdiana Stano2, Michele Bisaccia1, Luigi Meccariello3, Gabriele Falzarano4, Antonio Medici4, Marco Pellegrino1, Olga Bisaccia5, ...
26 March 2017
 26 March 2017
  238  
Ventsislav Mutafchiyski1, Georgi Popivanov1, Dimitar Penchev1, Albena Fakirova2, Ivan Inkov3, Rumen Popov4
 238 
Ventsislav Mutafchiyski1, Georgi Popivanov1, Dimitar Penchev1, Albena Fakirova2, Ivan Inkov3, Rumen Popov4
26 March 2017
 26 March 2017
  331  
Thulasikumar Ganapathy1, Marunraj Gnanasekaran2, Aravind Moorthy3
 331 
Thulasikumar Ganapathy1, Marunraj Gnanasekaran2, Aravind Moorthy3
26 March 2017
 26 March 2017
  286  
Daniele Maiettini1, Marta Rossi2, Michele Bisaccia3, Auro Caraffa3, Luigi Meccariello4, Gabriele Falzarano5, Antonio Medici5, Luigi Piscitelli3, Giulio Metro2, Alberto Rebonato1
 286 
Daniele Maiettini1, Marta Rossi2, Michele Bisaccia3, Auro Caraffa3, Luigi Meccariello4, Gabriele Falzarano5, Antonio Medici5, Luigi Piscitelli3, ...
26 March 2017